Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AON-D21 in Severe Community-Acquired Pneumonia
2023-505985-28-01Phase 2Completed
- Sponsor
- Aptarion Biotech
- Start
- Mar 2024
- Modality
- Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, MicroRNA (miRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Antisense Oligonucleotides (ASOs) → Long RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics
- Countries
- 5
01
Overview
Phase 2, randomised, double-blind trial in community-acquired pneumonia (CAP) comparing AON-D21 with Placebo (2 arms). Primary endpoint: Safety - treatment-emergent adverse events. Started Mar 2024; status: completed.
02
Drugs
AON-D21
03
Conditions
community-acquired pneumonia (CAP)
Beyond the preview
Go deeper on 2023-505985-28-01.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-505985-28-01.